Crizotinib and Doxorubicin Cooperatively Reduces Drug Resistance by Mitigating MDR1 to Increase Hepatocellular Carcinoma Cells Death

As the sixth most lethal cancers worldwide, hepatocellular carcinoma (HCC) has been treated with doxorubicin (Dox) for decades. However, chemotherapy resistance, especially for Dox is an even more prominent problem due to its high cardiotoxicity. To find a regimen to reduce Dox resistance, and ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Ming, Shi, Run, Gao, Zhen-Xing, Gao, Shan-Shan, Li, Jing-Feng, Li, Huan, Cui, Shu-Zhong, Hu, Wei-Min, Chen, Tian-Yun, Wu, Gui-Ru, Zhang, Jie, Xu, Jiang, Sy, Man-Sun, Li, Chaoyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170002/
https://www.ncbi.nlm.nih.gov/pubmed/34094940
http://dx.doi.org/10.3389/fonc.2021.650052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170002/
https://www.ncbi.nlm.nih.gov/pubmed/34094940
http://dx.doi.org/10.3389/fonc.2021.650052

Ejemplares similares